$PODD
INSULET CORP Stock $podd

$podd Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000114519718000015 Filed on November 02, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2018 Q1
Revenue	$164.9M	$151.1M	$123.6M
YoY Change	26.34%	24.08%	21.5%
Cost Of Revenue	$54.60M	$49.11M	$47.76M
YoY Change	7.06%	1.99%	12.87%
Gross Profit	$110.3M	$102.0M	$75.80M
YoY Change	38.73%	38.54%	27.61%
Gross Profit Margin	66.89%	67.5%	61.34%
Selling, General & Admin	$65.60M	$72.77M	$55.55M
YoY Change	6.67%	41.47%	17.67%
% of Gross Profit	59.47%	71.34%	73.28%
Research & Development	$28.50M	$22.34M	$20.27M
YoY Change	51.6%	10.9%	15.81%
% of Gross Profit	25.84%	21.9%	26.74%
Depreciation & Amortization	$4.400M	$4.120M	$3.522M
YoY Change	32.53%	7.85%	5.99%
% of Gross Profit	3.99%	4.04%	4.65%
Operating Expenses	$94.10M	$95.10M	$75.82M
YoY Change	17.19%	32.87%	17.17%
Operating Profit	$16.23M	$6.865M	$0.00
YoY Change	-2213.67%	235.37%	-100.0%
Interest Expense	-$5.300M	$6.846M	-$6.200M
YoY Change	-3.64%	-263.0%	34.78%
% of Operating Profit	-32.65%	99.72%
Other Income/Expense, Net		-$5.012M	-$6.236M
YoY Change		20.68%	36.37%
Pretax Income	$10.90M	$1.853M	-$6.236M
YoY Change	-257.97%	-187.99%	-36.89%
Income Tax	$1.000M	$194.0K	$300.0K
% Of Pretax Income	9.17%	10.47%
Net Earnings	$9.900M	$1.700M	-$6.600M
YoY Change	-244.31%	-176.34%	-33.85%
Net Earnings / Revenue	6.0%	1.13%	-5.34%
Basic Earnings Per Share	$0.17	$0.03	-$0.11
Diluted Earnings Per Share	$0.16	$0.03	-$0.11
COMMON SHARES
Basic Shares Outstanding	59.08M shares	59.02M shares	58.48M shares
Diluted Shares Outstanding		61.15M shares	58.48M shares

Balance Sheet

Concept	2018 Q4	2018 Q3	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$288.9M	$289.8M	$352.0M
YoY Change	-34.36%	5.08%	38.58%
Cash & Equivalents	$113.9M	$126.6M	$203.1M
Short-Term Investments	$175.0M	$163.3M	$148.9M
Other Short-Term Assets	$24.30M	$17.90M	$17.40M
YoY Change	145.45%	123.75%	112.2%
Inventory	$71.40M	$58.05M	$33.04M
Prepaid Expenses	$16.98M	$11.04M	$10.60M
Receivables	$63.30M	$69.95M	$50.38M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$461.3M	$445.7M	$547.1M
YoY Change	-14.12%	21.77%	62.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$258.4M	$229.4M	$153.0M
YoY Change	139.56%	159.27%	134.42%
Goodwill	$39.60M	$39.80M	$39.77M
YoY Change	-0.5%	-0.14%	0.19%
Intangibles	$10.38M
YoY Change	138.63%
Long-Term Investments	$140.8M	$145.5M	$164.1M
YoY Change	12.19%
Other Assets	$2.278M	$2.487M	$15.30M
YoY Change	15.69%	54.09%	2428.1%
Total Long-Term Assets	$467.4M	$440.6M	$292.9M
YoY Change	67.18%	228.0%	171.73%
TOTAL ASSETS
Total Short-Term Assets	$461.3M	$445.7M	$547.1M
Total Long-Term Assets	$467.4M	$440.6M	$292.9M
Total Assets	$928.7M	$886.3M	$840.0M
YoY Change	13.71%	77.14%	88.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$25.50M	$26.85M	$33.85M
YoY Change	4.45%	-6.29%	427.77%
Accrued Expenses	$90.20M	$68.17M	$45.76M
YoY Change	52.22%	51.83%	43.72%
Deferred Revenue	$1.200M	$2.210M	$4.981M
YoY Change	-49.07%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$3.451M
YoY Change
Total Short-Term Liabilities	$115.7M	$97.22M	$88.65M
YoY Change	34.5%	29.74%	125.12%
LONG-TERM LIABILITIES
Long-Term Debt	$592.0M	$584.5M	$569.9M
YoY Change	4.56%	69.44%	69.22%
Other Long-Term Liabilities	$8.900M	$6.668M	$6.301M
YoY Change	47.6%	7.53%	20.45%
Total Long-Term Liabilities	$600.9M	$591.2M	$576.2M
YoY Change	5.02%	68.35%	68.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$115.7M	$97.22M	$88.65M
Total Long-Term Liabilities	$600.9M	$591.2M	$576.2M
Total Liabilities	$716.6M	$688.4M	$661.1M
YoY Change	8.87%	61.56%	73.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$683.6M	-$693.5M	-$686.9M
YoY Change	-3.34%	-0.98%	-0.51%
Common Stock	$100.0K	$59.00K	$59.00K
YoY Change	72.41%	1.72%	1.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$212.1M	$197.9M	$170.6M
YoY Change
Total Liabilities & Shareholders Equity	$928.7M	$886.3M	$840.0M
YoY Change	13.71%	77.14%	88.78%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2018 Q1
OPERATING ACTIVITIES
Net Income	$9.900M	$1.700M	-$6.600M
YoY Change	-244.31%	-176.34%	-33.85%
Depreciation, Depletion And Amortization	$4.400M	$4.120M	$3.522M
YoY Change	32.53%	7.85%	5.99%
Cash From Operating Activities	$30.44M	$15.86M	-$4.266M
YoY Change	39.63%	-31.87%	-80.46%
INVESTING ACTIVITIES
Capital Expenditures	-$34.79M	-$37.62M	$35.37M
YoY Change	18.25%	330.43%	37.75%
Acquisitions
YoY Change
Other Investing Activities	-$5.990M	$11.01M	-$20.61M
YoY Change	-95.0%	-4.51%	24.08%
Cash From Investing Activities	-$40.78M	-$26.62M	-$55.99M
YoY Change	-72.69%	-1057.55%	32.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			-$2.261M
YoY Change			-135.69%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.590M	1.090M	-$8.870M
YoY Change	-100.53%	-55.69%	-403.04%
NET CHANGE
Cash From Operating Activities	30.44M	15.86M	-$4.266M
Cash From Investing Activities	-40.78M	-26.62M	-$55.99M
Cash From Financing Activities	-1.590M	1.090M	-$8.870M
Net Change In Cash	-11.93M	-9.670M	-$69.12M
YoY Change	-107.0%	-133.91%	12.96%
FREE CASH FLOW
Cash From Operating Activities	$30.44M	$15.86M	-$4.266M
Capital Expenditures	-$34.79M	-$37.62M	$35.37M
Free Cash Flow	$65.23M	$53.48M	-$39.64M
YoY Change	27.35%	67.02%	-16.57%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
CY2017	podd	Tax Cuts And Jobs Act Of2017 Transition Tax For Accumulated Foreign Earnings Tax Expense Increase Decrease In Valuation Allowance TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsTaxExpenseIncreaseDecreaseInValuationAllowance	-800000	USD
CY2017	podd	Tax Cuts And Jobs Act Of2017 Transition Tax For Accumulated Foreign Earnings Tax Expense Reduction In Net Operating Loss TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsTaxExpenseReductionInNetOperatingLoss	-800000	USD
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	podd	Interestand Other Expense Total InterestandOtherExpenseTotal	29172000	USD
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	INSULET CORPORATION
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Trading Symbol TradingSymbol	PODD
CY2017Q3	podd	Debt Instrument Stated Coupon Rate Interest Expense DebtInstrumentStatedCouponRateInterestExpense	1449000	USD
	podd	Debt Instrument Stated Coupon Rate Interest Expense DebtInstrumentStatedCouponRateInterestExpense	4276000	USD
CY2018Q3	podd	Debt Instrument Stated Coupon Rate Interest Expense DebtInstrumentStatedCouponRateInterestExpense	2440000	USD
	podd	Debt Instrument Stated Coupon Rate Interest Expense DebtInstrumentStatedCouponRateInterestExpense	7382000	USD
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001145197
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	59077244	shares
CY2018Q3	podd	Finite Lived Intangible Assets Amortization Expense Thereafter FiniteLivedIntangibleAssetsAmortizationExpenseThereafter	1313000	USD
CY2018Q3	podd	Finited Lived Intangible Assets Excluding Software In Process Of Development Net FinitedLivedIntangibleAssetsExcludingSoftwareInProcessOfDevelopmentNet	7791000	USD
	podd	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	10502000	USD
	podd	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	2938000	USD
	podd	Increase Decrease In Accounts Receivable And Unbilled Revenue IncreaseDecreaseInAccountsReceivableAndUnbilledRevenue	19757000	USD
	podd	Increase Decrease In Accounts Receivable And Unbilled Revenue IncreaseDecreaseInAccountsReceivableAndUnbilledRevenue	24581000	USD
CY2017Q3	podd	Interestand Other Expense Total InterestandOtherExpenseTotal	5566000	USD
	podd	Interestand Other Expense Total InterestandOtherExpenseTotal	16461000	USD
CY2018Q3	podd	Interestand Other Expense Total InterestandOtherExpenseTotal	9803000	USD
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	59256000	USD
CY2018Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	68169000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	24413000	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	26845000	USD
CY2017Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3542000	USD
CY2018Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3863000	USD
CY2017Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	55914000	USD
CY2018Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	73428000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	53373000	USD
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	69950000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	59256000	USD
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	68169000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	9273000	USD
CY2018Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	10190000	USD
CY2017Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	34942000	USD
CY2018Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	32265000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-493000	USD
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2452000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	866206000	USD
CY2018Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	893829000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8897000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23552000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16088000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31205000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2541000	USD
CY2018Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3478000	USD
CY2017Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3612000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	10690000	USD
CY2018Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	6702000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	19840000	USD
CY2017Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	505000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1495000	USD
CY2018Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	661000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1950000	USD
CY2017Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	4117000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	12185000	USD
CY2018Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	7363000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	21790000	USD
CY2017Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	800000	USD
CY2018Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1300000	USD
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11850509	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11914219	shares
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10754004	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14212915	shares
CY2017Q4	us-gaap	Assets Assets	816744000	USD
CY2018Q3	us-gaap	Assets Assets	886306000	USD
CY2018Q1	us-gaap	Assets Assets	840004000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	537171000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	445712000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	547105000	USD
CY2017Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	167479000	USD
CY2018Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	163281000	USD
CY2017	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	12700000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4000000	USD
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	5000000	USD
	us-gaap	Capitalized Contract Cost Impairment Loss CapitalizedContractCostImpairmentLoss	0	USD
CY2018Q3	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	22400000	USD
CY2017Q4	us-gaap	Capitalized Contract Cost Net Current CapitalizedContractCostNetCurrent	0	USD
CY2018Q3	us-gaap	Capitalized Contract Cost Net Current CapitalizedContractCostNetCurrent	6869000	USD
CY2018Q3	us-gaap	Capitalized Contract Cost Net Current CapitalizedContractCostNetCurrent	6900000	USD
CY2017Q4	us-gaap	Capitalized Contract Cost Net Noncurrent CapitalizedContractCostNetNoncurrent	0	USD
CY2018Q3	us-gaap	Capitalized Contract Cost Net Noncurrent CapitalizedContractCostNetNoncurrent	15600000	USD
CY2018Q3	us-gaap	Capitalized Contract Cost Net Noncurrent CapitalizedContractCostNetNoncurrent	15570000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	272577000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	126563000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-34941000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-146014000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	126563000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	137174000	USD
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102233000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	272577000	USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58319348	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	59068586	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58319348	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	59068586	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	58000	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	59000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1822000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19368000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1593000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8560000	USD
CY2017Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2356000	USD
CY2018Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2210000	USD
CY2018Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4981000	USD
CY2018Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	600000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2500000	USD
CY2018Q3	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	USD
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	USD
CY2017Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	48151000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	135583000	USD
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	49107000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	139060000	USD
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	170448000	USD
CY2018Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	150439000	USD
CY2018Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	80	Security
CY2017Q4	us-gaap	Deferred Costs And Other Assets DeferredCostsAndOtherAssets	1969000	USD
CY2018Q3	us-gaap	Deferred Costs And Other Assets DeferredCostsAndOtherAssets	18057000	USD
CY2017Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	14543000	USD
CY2018Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	12568000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10533000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11254000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	487000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-674000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1280000	USD
CY2018Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	38883000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5329000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6558000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2101000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	555000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	771000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1771000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	9680000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	14349000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4351000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7791000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22718000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	62322000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	38420000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	85914000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	39840000	USD
CY2018Q3	us-gaap	Goodwill Goodwill	39774000	USD
CY2018Q3	us-gaap	Goodwill Goodwill	39800000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2017Q3	us-gaap	Gross Profit GrossProfit	73624000	USD
	us-gaap	Gross Profit GrossProfit	197661000	USD
CY2018Q3	us-gaap	Gross Profit GrossProfit	101969000	USD
	us-gaap	Gross Profit GrossProfit	259856000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2106000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-19653000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1853000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-5662000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	121000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	318000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	300000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	194000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	200000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	939000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	900000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	537000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2761000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-428000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	25279000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	668000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	400000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1290000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5258000	USD
CY2017Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	4709000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	14512000	USD
CY2018Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	17187000	USD
CY2018Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	900000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2600000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	658228000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	688377000	USD
CY2018Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	6846000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	22054000	USD
CY2017Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7729000	USD
CY2018Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	35473000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	33793000	USD
CY2018Q3	us-gaap	Inventory Net InventoryNet	58050000	USD
CY2018Q1	us-gaap	Inventory Net InventoryNet	33040000	USD
CY2017Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2146000	USD
CY2018Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	5390000	USD
CY2017Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	23918000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	661124000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	816744000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	886306000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	840004000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	86025000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	97224000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	88650000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	566173000	USD
CY2018Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	584485000	USD
CY2017Q4	us-gaap	Long Term Investments LongTermInvestments	125549000	USD
CY2018Q3	us-gaap	Long Term Investments LongTermInvestments	145539000	USD
CY2015Q2	us-gaap	Loss Contingency Claims Dismissed Number LossContingencyClaimsDismissedNumber	2	LegalMatter
CY2015Q2	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	3	LegalMatter
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6650000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-7081000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-61485000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-143719000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	19407000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	5460000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-2227000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-19971000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	1659000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-6601000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4153000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13034000	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5012000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-16852000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	71577000	USD
	us-gaap	Operating Expenses OperatingExpenses	204280000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	95104000	USD
	us-gaap	Operating Expenses OperatingExpenses	248666000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	2047000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6619000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	6865000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	11190000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9846000	USD
CY2018Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	19548000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1969000	USD
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2487000	USD
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15295000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	329000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	594000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	4000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1055000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	405000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	603000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-66000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1959000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	76000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	9000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-70000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-904000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6030000	USD
CY2018Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6668000	USD
CY2018Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6301000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	556000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1478000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1834000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5202000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	519000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-235000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	800000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3816000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	13846000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	115056000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	145575000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	47813000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	127559000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9949000	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	17905000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15517000	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9949000	USD
CY2018Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11036000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10735000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13464000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	101384000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	129415000	USD
CY2016Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	4388000	USD
CY2017Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	4817000	USD
CY2017Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	4997000	USD
CY2017Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	5337000	USD
CY2018Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	5503000	USD
CY2018Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	5718000	USD
CY2017Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	1653000	USD
CY2018Q3	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	2303000	USD
CY2017Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	3684000	USD
CY2018Q3	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	3415000	USD
CY2017Q3	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1303000	USD
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	2514000	USD
CY2018Q3	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1548000	USD
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	4883000	USD
CY2017Q3	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	1483000	USD
	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	3123000	USD
CY2018Q3	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	1763000	USD
	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	5264000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	107864000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	229433000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1502000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2588000	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	6699000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	269000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	0	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20141000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	55670000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21762000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	60092000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	500000	USD
CY2018Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2700000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-707255000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-693507000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-686906000	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	121775000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	333244000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	151076000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	398916000	USD
CY2017Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	28718000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	86288000	USD
CY2018Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	34922000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	102660000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	23551000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	31205000	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2077854	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	34.40
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	21419000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	162206	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	287199	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	208898000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3377220	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3117326	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	35.10
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	38.94
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	203882000	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3019139	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	33.11
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	40.45
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	77.05
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	148671000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y6M25D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	384887	shares
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	9733	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	158516000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	197929000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	178880000	USD
CY2017Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	0	USD
CY2018Q3	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	9963000	USD
CY2018Q1	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	5119000	USD
CY2018Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58099593	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57924920	shares
CY2018Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61146466	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58779672	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58099593	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57924920	shares
CY2018Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59016863	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58779672	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of the Business </font></div><div style="line-height:120%;padding-top:12px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Insulet Corporation (the "Company") is primarily engaged in the development, manufacturing and sale of its proprietary Omnipod Insulin Management System (the “Omnipod System”), an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. There are two</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">primary types of insulin therapy practiced today: multiple daily injection (“MDI”) therapy using syringes or insulin pens; and pump therapy using insulin pumps. Insulin pumps are used to perform continuous subcutaneous insulin infusion, or insulin pump therapy, and typically use a programmable device and an infusion set to administer insulin into the person’s body. Insulin pump therapy has been shown to provide people with insulin-dependent diabetes with numerous advantages relative to MDI therapy. The Company estimates that approximately one-third of the Type 1 diabetes population in the United States use insulin pump therapy, and that less than 10% of the Type 2 diabetes population in the United States who are insulin-dependent use insulin pump therapy.</font><font style="font-family:inherit;font-size:10pt;color:#ff0000;"> </font><font style="font-family:inherit;font-size:10pt;">The Omnipod System features a small, lightweight, self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time (the "Pod"), and its wireless companion, the handheld Personal Diabetes Manager ("PDM"). The Omnipod System, which features two discreet, easy-to-use devices, communicates wirelessly, provides for virtually pain-free automated cannula insertion and eliminates the need for traditional MDI therapy or the use of traditional pump and tubing. The Company believes that the Omnipod System’s unique proprietary design and features allow people with insulin-dependent diabetes to manage their diabetes with unprecedented freedom, comfort, convenience, and ease.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial sales of the Omnipod System began in the United States in 2005. The Company sells the Omnipod System through direct sales to customers or through intermediaries. The Omnipod System is currently available in multiple countries in Europe, as well as in Canada and Israel. On July 1, 2018, the Company commenced direct sales of the Omnipod System in Europe following the expiration of its distribution agreement on June 30, 2018 with Ypsomed Distribution AG ("Ypsomed" or the "European Distributor"). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to using the Omnipod System for insulin delivery, the Company also partners with global pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas. The majority of the Company's drug delivery revenue currently consists of sales of Amgen's Neulasta Onpro kit. </font></div><div style="line-height:120%;padding-top:12px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To lower manufacturing costs, increase supply redundancy, add capacity closer to its largest customer base and support growth, the Company is constructing a highly-automated manufacturing facility in Acton, Massachusetts, with planned production out of the facility beginning in early 2019. The facility will also serve as the Company's global headquarters.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates in Preparation of Financial Statements</font></div><div style="line-height:120%;padding-top:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in the application of certain of its significant accounting policies that may materially affect the reported amounts of assets, liabilities, equity, revenue and expenses. Actual results may differ from those estimates. See Note 3 related to the Company's adoption of Accounting Standards Update No. 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers, </font><font style="font-family:inherit;font-size:10pt;">for a discussion of judgments associated with the recognition of revenue and deferral of cost to obtain a contract.</font></div></div>

Files In Submission

Name	View Source	Status
0001145197-18-000015-index-headers.html	Edgar Link	pending
0001145197-18-000015-index.html	Edgar Link	pending
0001145197-18-000015.txt	Edgar Link	pending
0001145197-18-000015-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
podd-20180930.xml	Edgar Link	completed
podd-20180930.xsd	Edgar Link	pending
podd-20180930_cal.xml	Edgar Link	unprocessable
podd-20180930_def.xml	Edgar Link	unprocessable
podd-20180930_lab.xml	Edgar Link	unprocessable
podd-20180930_pre.xml	Edgar Link	unprocessable
podd-2018x09x30_10q.htm	Edgar Link	pending
podd-exx101_20180930x10q.htm	Edgar Link	pending
podd-exx311_20180930x10q.htm	Edgar Link	pending
podd-exx312_20180930x10q.htm	Edgar Link	pending
podd-exx321_20180930x10q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PODD
INSULET CORP Stock $podd

2018 Q4 Form 10-Q Financial Statement

#000114519718000015 Filed on November 02, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PODD INSULET CORP Stock $podd

2018 Q4 Form 10-Q Financial Statement

#000114519718000015 Filed on November 02, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PODD
INSULET CORP Stock $podd